Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Prenatal Diagnostic Centre and Cord Blood Bank, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
Department of Computer Science, The University of Hong Kong, Hong Kong SAR, China; School of Biomedical Sciences, The University of Hong Kong, Hong Kong SAR, China; Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Mol Ther. 2020 Dec 2;28(12):2642-2661. doi: 10.1016/j.ymthe.2020.07.024. Epub 2020 Jul 25.
Bietti's crystalline dystrophy (BCD) is an incurable retinal disorder caused by the polypeptide 2 of cytochrome P450 family 4 subfamily V (CYP4V2) mutations. Patients with BCD present degeneration of retinal pigmented epithelial (RPE) cells and consequent blindness. The lack of appropriate disease models and patients' RPE cells limits our understanding of the pathological mechanism of RPE degeneration. In this study, using CYP4V2 mutant pluripotent stem cells as disease models, we demonstrated that RPE cells with CYP4V2 mutations presented a disrupted fatty acid homeostasis, which were characterized with excessive accumulation of poly-unsaturated fatty acid (PUFA), including arachidonic acid (AA) and eicosapentaenoic acid (EPA). The PUFA overload increased mitochondrial reactive oxygen species, impaired mitochondrial respiratory functions, and triggered mitochondrial stress-activated p53-independent apoptosis in CYP4V2 mutant RPE cells. Restoration of the mutant CYP4V2 using adeno-associated virus 2 (AAV2) can effectively reduce PUFA deposition, alleviate mitochondria oxidative stresses, and rescue RPE cell death in BCD RPE cells. Taken together, our results highlight a role of PUFA-induced mitochondrial damage as a central node to potentiate RPE degeneration in BCD patients. AAV2-mediated gene therapy may represent a feasible strategy for the treatment of BCD.
Bietti 结晶样营养不良症 (BCD) 是一种由细胞色素 P450 家族 4 亚家族 V 多肽 2 (CYP4V2) 突变引起的不可治愈的视网膜疾病。BCD 患者表现出视网膜色素上皮 (RPE) 细胞变性,继而失明。缺乏适当的疾病模型和患者的 RPE 细胞限制了我们对 RPE 变性病理机制的理解。在这项研究中,我们使用 CYP4V2 突变的多能干细胞作为疾病模型,证明了具有 CYP4V2 突变的 RPE 细胞表现出脂肪酸稳态失调,其特征是多不饱和脂肪酸 (PUFA) ,包括花生四烯酸 (AA) 和二十碳五烯酸 (EPA) 过度积累。PUFA 过载增加了线粒体活性氧,损害了线粒体呼吸功能,并在 CYP4V2 突变的 RPE 细胞中引发线粒体应激激活的 p53 非依赖性细胞凋亡。使用腺相关病毒 2 (AAV2) 恢复突变的 CYP4V2 可有效减少 PUFA 沉积,减轻线粒体氧化应激,并挽救 BCD RPE 细胞中的 RPE 细胞死亡。总之,我们的结果强调了 PUFA 诱导的线粒体损伤作为增强 BCD 患者 RPE 变性的中心节点的作用。AAV2 介导的基因治疗可能是治疗 BCD 的一种可行策略。